Last reviewed · How we verify
MP1032
At a glance
| Generic name | MP1032 |
|---|---|
| Sponsor | MetrioPharm AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis (PHASE2)
- MP1032 Treatment in Patients With Moderate to Severe COVID-19 (PHASE2)
- Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MP1032 CI brief — competitive landscape report
- MP1032 updates RSS · CI watch RSS
- MetrioPharm AG portfolio CI